



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

DL-Laudanosine

Cat. No.:	HY-122489		
CAS No.:	1699-51-0		
Molecular Formula:	C ₂₁ H ₂₇ NO ₄		
Molecular Weight:	357.44		
Target:	Drug Metabolite		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (279.77 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	2.7977 mL	13.9884 mL	27.9767 mL
	5 mM	0.5595 mL	2.7977 mL	5.5953 mL
	10 mM	0.2798 mL	1.3988 mL	2.7977 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.99 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.99 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.99 mM); Clear solution 			

BIOLOGICAL ACTIVITY

Description	DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity ^[1] .
In Vivo	DL-Laudanosine (Laudanosine) appears to be unique in its ability to produce cerebral stimulation in lightly anaesthetized animals and it is reported to cause arousal from anaesthesia in subconvulsive doses ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male CFLP mice weighing 18-25 g, and male Wistar rats weighing 120-150 g [2].
Dosage:	10-20 mg/kg.
Administration:	IV.
Result:	Caused convulsions and hind limb extensions.

REFERENCES

[1]. V Fodale, et al. Laudanosine, an Atracurium and Cisatracurium Metabolite. Eur J Anaesthesiol. 2002 Jul;19(7):466-73.

[2]. D J Chapple, et al. Cardiovascular and Neurological Effects of Laudanosine. Studies in Mice and Rats, and in Conscious and Anaesthetized Dogs. Br J Anaesth. 1987 Feb;59(2):218-25.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA